ReviewThe Lancet. Oncology2023
National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities.
Open access · greenAbstract readReview
In one paragraph
Review in The Lancet. Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
9.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Focused ultrasound for brain metastases.Neuro-oncology advances · 2026Review
- Understanding the unmet needs of patients with brain metastases referred for stereotactic radiotherapy and their caregivers: A prospective cohort study.Neuro-oncology practice · 2026Article
- Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative.Neuro-oncology · 2026Review
- Clinical features and prognostic factors of ovarian cancer brain metastases from ovarian cancer: a retrospective multicenter study of 129 cases.BMC cancer · 2025Article
- Value of artificial intelligence in neuro-oncology.The Lancet. Digital health · 2025Review
- HIF-1 promotes murine breast cancer brain metastasis by increasing production of integrin β3-containing extracellular vesicles.The Journal of clinical investigation · 2025Article
- Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care.Nature reviews. Clinical oncology · 2025Review
- Article
- Factors associated with local failure after stereotactic radiation to the surgical bed of patients with a single breast cancer metastasis.Acta neurochirurgica · 2025Article
- Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview.Neuro-oncology · 2025Review
- Efficacy of 3D-TSE sequence-based radiosurgery in prolonging time to distant intracranial failure: A session-wise analysis in a histology-diverse patient cohort.Neuro-oncology · 2025Article
- Leptomeningeal metastatic disease: new frontiers and future directions.Nature reviews. Clinical oncology · 2025Review
- Return to work in younger patients with brain metastases who survived for 2 years or more.Journal of neuro-oncology · 2025Article
- Review
- "Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized tools.European journal of cancer (Oxford, England : 1990) · 2024Review
- Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion.NPJ breast cancer · 2024Article
- From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities.Clinical & experimental metastasis · 2024Review
- Biological Insights and Radiation-Immuno-Oncology Developments in Primary and Secondary Brain Tumors.Cancers · 2024Review
- Stereotactic Radiosurgery and Stereotactic Fractionated Radiotherapy in the Management of Brain Metastases.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 20 institutions in 1 country.
Michelle M KimDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. Electronic address: michekim@med.umich.edu.
Minesh P MehtaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
DeeDee K SmartRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Patricia S SteegWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Julie A HongRadiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
Michael G EspeyRadiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
Pataje G PrasannaRadiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
Laura CrandonTouch4Life, Clarksville, MD, USA.
Christine HodgdonGRASP, Baltimore, MD, USA.
Niki KozakSanta Maria, CA, USA.
Terri S ArmstrongNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Aki MorikawaDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Nicole WillmarthAmerican Brain Tumor Association, Chicago, IL, USA.
Kirk TannerNational Brain Tumor Society, Newton, MA, USA.
Adrienne BoireDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Melanie Hayden GephartDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.
Kim A MargolinSt John's Cancer Institute, Santa Monica, CA, USA.
Jona Hattangadi-GluthDepartment of Radiation Oncology, University of California San Diego Health, La Jolla, CA, USA.
Hussein TawbiDepartment of Melanoma Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daniel M TrifilettiDepartment of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.
Caroline ChungDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Upal Basu-RoyLUNGevity Foundation, Chicago, IL, USA.
Robyn BurnsMelanoma Research Foundation, Washington, DC, USA.
Isabella C Glitza OlivaDepartment of Melanoma Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ayal A AizerDepartment of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA.
Carey K AndersDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
Joanne DavisThe Radiosurgery Society, San Jose, CA, USA.
Manmeet S AhluwaliaDepartment of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Veronica ChiangDepartment of Neurosurgery and Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
Jing LiDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rupesh KotechaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Silvia C FormentiDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Vinai GondiDepartment of Radiation Oncology, Northwestern Medicine Cancer Center Warrenville and Proton Center, Warrenville, IL, USA.
Paul W SperdutoDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Jill S Barnholtz-SloanInformatics and Data Science Program, Center for Biomedical Informatics and Information Technology, Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Jordi RodonDepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eudocia Q LeeCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mustafa KhasrawPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Debra Nana YeboaDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Priscilla K BrastianosDivision of Hematology/Oncology and Division of Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Evanthia GalanisDepartment of Oncology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA.
C Norman ColemanRadiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
Mansoor M AhmedRadiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA. Electronic address: ahmedmm@mail.nih.gov.
National Cancer Institute · USThe University of Texas MD Anderson Cancer Center · USBaptist Health South Florida · USDuke Medical Center · USUniversity of Michigan–Ann Arbor · USAmerican Brain Tumor Association · USCenter for Cancer Research · USCenter for Neuro-Oncology · USCornell University · USDana-Farber Brigham Cancer Center · USDuke University Hospital · USLUNGevity Foundation · USMassachusetts General Hospital · USMayo Clinic in Arizona · USMelanoma Research Foundation · USMemorial Sloan Kettering Cancer Center · USNational Brain Tumor Society · USNorthwestern Medicine · USStanford University · USSt. John's School · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MMolecular Analysis of Breast Cancer Metastasis to the BrainZIABC010538 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STEEG, PATRICIA SCHRIVER · 2009 to 2025
$17.1MTOOLKIT CoreU54CA261717 · NCI · STANFORD UNIVERSITY · PI Melanie Hayden Gephart · 2021 to 2026
$8.9MNeuropsychological outcome measures in patients receiving whole brain radiationZIABC011333 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SMART, DEEDEE · 2010 to 2025
$4.6MIdentification of genomic drivers of brain metastases in lung adenocarcinomaR01CA227156 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, CARTER, SCOTT · 2018 to 2022
$3.5MRole of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaR01CA270027 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIMOTHY CLOUGHESY, Benjamin M. Ellingson · 2022 to 2026
$3.0MQuantitative molecular MR-PET imaging of glycolysis in glioblastomaR01CA279984 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Benjamin M. Ellingson, David A. Nathanson · 2023 to 2026
$2.4MTumor heterogeneity in breast cancer brain metastasis after brain radiationZIABC011330 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SMART, DEEDEE · 2010 to 2017
$1.5MImage-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal RegionsR01CA238783 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HATTANGADI-GLUTH, JONA A · 2019 to 2021
$737kDr. Kim R50 Research Specialist Clinician 2022R50CA276015 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Michelle Miran Kim · 2023 to 2026
$687kIntramural NIH HHS ZIA BC010538Intramural NIH HHS ZIA BC011330NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA227156NCI NIH HHS R01 CA238783NCI NIH HHS R01 CA270027NCI NIH HHS R01 CA279984NCI NIH HHS R50 CA276015NCI NIH HHS U54 CA261717
Abstract
Brain metastases are an increasing global public health concern, even as survival rates improve for patients with metastatic disease. Both metastases and the sequelae of their treatment are key determinants of the inter-related priorities of patient survival, function, and quality of life, mandating a multidimensional approach to clinical care and research. At a virtual National Cancer Institute Workshop in September, 2022, key stakeholders convened to define research priorities to address the crucial areas of unmet need for patients with brain metastases to achieve meaningful advances in patient outcomes. This Policy Review outlines existing knowledge gaps, collaborative opportunities, and specific recommendations regarding consensus priorities and future directions in brain metastases research. Achieving major advances in research will require enhanced coordination between the ongoing efforts of individual organisations and consortia. Importantly, the continual and active engagement of patients and patient advocates will be necessary to ensure that the directionality of all efforts reflects what is most meaningful in the context of patient care.
Indexed as
Biomedical ResearchBrain NeoplasmsConsensusHumansNational Cancer Institute (U.S.)Quality of LifeUnited States
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.